Skip to main content
SpringerLink
Log in

2-Chlorodeoxyadenosine treatment of lymphoma

  • Chapter
Advances in Lymphoma Research

Part of the book series: Cancer Treatment and Research ((CTAR,volume 85))

Abstract

2-Chlorodeoxyadenosine (2-CdA) [Cladribine, Leustatin (Ortho Biotech, Raritan, NJ)] is a newer purine analog with major activity in the treatment of a variety of indolent B- and T-cell lymphoid malignancies. The activity of 2-CdA has been demonstrated in hairy cell leukemia [1-4], chronic lymphocytic leukemia [5-7], non-Hodgkin’s lymphoma [8-12], cutaneous T-cell lymphoma [13], and the myeloid leukemias [14-16]. 2-CdA gained wide attention in 1990 for the treatment of patients with hairy cell leukemia, a disease in which a single course of the drug induces long-lasting complete remissions in the vast majority of patients treated. Along with fludarabine and 2’-deoxycoformycin, these newer purine analogs have revolutionized the treatment of the indolent lymphoproliferative disorders and stimulated tremendous interest in the hematologic malignancy field.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Piro LD, Carrera CJ, Carson DA, Beutler E (1990). Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322:1117–1121.

    Article  PubMed  CAS  Google Scholar 

  2. Piro LD, Saven A, Ellison D, Thurston D, Carson DA, Beutler E (1992). Prolonged complete remissions following 2-chlorodeoxyadenosine (2-CdA) in hairy cell leukemia (HCL). Proc Am Soc Clin Oncol 11:846 (abstract).

    Google Scholar 

  3. Tallman M, Hakimian D, Variakojis D, et al. (1992). A single cycle of 2-chloro-deoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 80:2203–2209.

    PubMed  CAS  Google Scholar 

  4. Juliusson G, Liliemark J (1992). Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA): relation to opportunistic infections. Blood 79:888–894.

    PubMed  CAS  Google Scholar 

  5. Piro LD, Carrera CJ, Beutler E, Carson DA (1988). 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 72:1069–1073.

    PubMed  CAS  Google Scholar 

  6. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD (1991). 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymphoma 5(Suppl):133–138.

    Article  Google Scholar 

  7. Juliusson G, Liliemark J (1993). High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 11:679–689.

    PubMed  CAS  Google Scholar 

  8. Kay AC, Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD (1992). 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 10:371–377.

    PubMed  CAS  Google Scholar 

  9. Hoffman M, Tallman M, Hakimian D, et al. (1994). 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodkin’s lymphoma. J Clin Oncol 12:788–792.

    PubMed  CAS  Google Scholar 

  10. Hickish T, Serafinowski P, Cunningham D, et al. (1993). 2-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer 67:139–143.

    Article  PubMed  CAS  Google Scholar 

  11. Saren A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L (1995). 2 chlorodeoxyadenosine activity in untreated, indolent non-Hodgkin’s lymphoma. Blood 86:1710–1716.

    Google Scholar 

  12. Piro LD, Petroni G, Barcos M, Johnson J, Saven A, Peterson B (1995). Bolus infusion of 2-chlorodeoxyadenosine (2-CdA) as first-line therapy of low grade non-Hodgkin’s lymphoma (NHL): CALGB 9153. Blood 86:1082 (Abstract).

    Google Scholar 

  13. Dimopoulos MA, Kanstarjian H, Weber D, O’Brien S, Estey E, Delasalle K, et al. (1994). Primary Therapy of Waldenström macroglobalinemia with 2-chlorodeoxyadenosine. J Clin Oncol 12:2694–2698.

    PubMed  CAS  Google Scholar 

  14. Dimopoulos MA, Kantarjian HM, Estey EH, et al. (1993). Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 118:195–198.

    PubMed  CAS  Google Scholar 

  15. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD (1992). 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 80:587–592.

    PubMed  CAS  Google Scholar 

  16. Saven A, Lemon RH, Figueroa ML, Kosty M, Ellison DJ, Beutler E, Piro LD (1994). Complete hematologic remissions in stable-phase philadelphia-chromosome positive, chromic myelogenous leukemia following 2-chloreoxyadenosine. Cancer 73:2953–2963.

    Article  PubMed  CAS  Google Scholar 

  17. Santana VM, Mirro J Jr, Harwood FC, et al. (1991). A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol 9:416–422.

    PubMed  CAS  Google Scholar 

  18. Santana VM, Mirro J Jr, Kearns C, Schell MJ, Crom W, Blakley RL (1992). 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 10:364–370.

    PubMed  CAS  Google Scholar 

  19. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA (1985). Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest 75:377–383.

    Article  PubMed  CAS  Google Scholar 

  20. Seto S, Carrera CJ, Wasson DB, Carson DA (1986). Inhibition of DNA repair by deoxyadenosine in resting human lymphocytes. J Immunol 136:2839–2843.

    PubMed  CAS  Google Scholar 

  21. Carson DA, Kaye J, Seegmiller JE (1978). Differential sensitivity of human leukemic T cell lines and B cell lines to growth inhibition by deoxyadenosine. J Immunol 121:1726–1731.

    PubMed  CAS  Google Scholar 

  22. Carson DA, Wasson DB, Kaye J, et al. (1980). Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs towards malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci USA 77:6865–6869.

    Article  PubMed  CAS  Google Scholar 

  23. Avery T, Rehg J, Lumm W, Harwood FC, Santana VM, Blackley RL (1989). Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice. Cancer Res 49:4972–4978.

    PubMed  CAS  Google Scholar 

  24. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ (1972). Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2:1067–1069.

    Article  PubMed  CAS  Google Scholar 

  25. Cohen A, Hirshhorn R, Horowitz SD, et al. (1978). Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci USA 75:472–476.

    Article  PubMed  CAS  Google Scholar 

  26. Carrera CJ, Carson DA (1987). Enzyme deficiencies associated with immunological disorders. In Stamatoyannopoulos G, Nienhius AW, Leder P, Majerus PW (eds), The Molecular Basis of Blood Diseases. New York: W.B. Saunders, pp. 407–449.

    Google Scholar 

  27. Chunduru SK, Blakley RL (1991). Effect of 2′-chlorodeoxyadenosine triphosphate on nucleotide incorporation rate of human polymerase α and β. Proc Am Assoc Cancer Res 97:17 (abstract).

    Google Scholar 

  28. Carrera CJ, Piro LD, Miller WE, Carson DA, Beutler E (1987). Remission induction in hairy cell leukemia by treatment with 2-chlorodeoxyadenosine: role of DNA strand breaks and NAD depletion. Clin Res 35:597A (abstract).

    Google Scholar 

  29. Carrera CJ, Terai C, Piro L, Saven A, Beutler E, Carson D (1991). 2-Chlorodeoxyadenosine chemotherapy triggers programmed cell death in normal and malignant lymphocytes. J Purine Pyrimidine Res 2(Suppl 1):15–38.

    Google Scholar 

  30. Kerr JF, Wyllie AH, Currie AR (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239–257.

    Article  PubMed  CAS  Google Scholar 

  31. Carson DA, Ribeiro JM (1993). Apoptosis and disease. Lancet 341:1251–1254.

    Article  PubMed  CAS  Google Scholar 

  32. Miyashita T, Reed JC (1993). Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151–157.

    PubMed  CAS  Google Scholar 

  33. Carson DA, Wasson DB, Beutler E (1981). Antileukemia and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc Natl Acad Sci USA 81:2232–2236.

    Article  Google Scholar 

  34. Vahdat L, Wong ET, Wile MJ, Rosenblum M, Foley KM, Warren RP (1994). Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood 84:3429–3434.

    PubMed  CAS  Google Scholar 

  35. Larson RA, Mick R, Spielberger RT, O’Brien SM, Ratain MJ (1994). Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. J Clin Oncol 14:188–195.

    Google Scholar 

  36. Liliemark J, Albertioni F, Hassan M, Pettersson B, Juliusson G (1992). On the bioavailability of oral and subcutaneous 2-chloro-2’-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 10:1514–1518.

    PubMed  CAS  Google Scholar 

  37. Portlock CS (1990). Management of the low-grade non-Hodgkin’s lymphomas. Semin Oncol 17:51–59.

    PubMed  CAS  Google Scholar 

  38. Cerny T, Fey MF, Von Rohr A, et al. (1993). 2-Chlorodeoxyadenosine (2-CdA) for the treatment of various haematological malignancies. Eight Symposium July 9-13, Basel, Switzerland, abstract 160. Mol Biol Hematopoiesis.

    Google Scholar 

  39. Kahn J, Kaplan L, Northfelt D, et al. (1991). 2-chlorodeoxyadenosine (2-CdA) for AIDS-associated non-Hodgkin’s lymphoma (NHL): a phase I study. Proc Am Soc Clin Oncol 10:34 (abstract).

    Google Scholar 

  40. Beutler E, Piro LD, Saven A, et al. (1991). 2-Chlorodeoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleotide. Leuk Lymphoma 5:1–8.

    Article  Google Scholar 

  41. Beutler E (1992). Cladribine (2-chlorodeoxyadenosine). Lancet 340:952–956.

    Article  PubMed  CAS  Google Scholar 

  42. MacKenzie MR, Fudenberg HH (1972). Macroglobulinemia — an analysis of 40 patients. Blood 39:874–889.

    PubMed  CAS  Google Scholar 

  43. Kaye FJ, Bunn PA, Steinberg SM, et al. (1989). A randomized trial comparing combination electron-bean radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321:1784–1790.

    Article  PubMed  CAS  Google Scholar 

  44. Lee E, Kuzel T, Samuelson E, Tallman M, Roenigk H, Rosen S (1993). Phase II trial of 2-chlorodeoxyadenosine (2-CdA) for the treatment of cutaneous T-cell lymphoma (CTCL). Blood 82(Suppl 1):552 (abstract).

    Google Scholar 

  45. O’Brien S, Kurzrock R, Duvic M, et al. (1994). 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 84:733–738.

    PubMed  Google Scholar 

  46. Von Hoff DD, Dahlberg S, Hartstock RJ, Eyre HJ (1990). Activity of fludarabine monophos-phate in patients with advanced mycosis fungoides: a Southwest Oncology Group Study. J Natl Cancer Inst 82:1353–1355.

    Article  Google Scholar 

  47. Grever MR, Bisaccia E, Scarborough DA, Metz EN, Neidhart JA (1983). An investigation of 2′-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 61:279–282.

    PubMed  CAS  Google Scholar 

  48. Cummings FJ, Kim K, Neiman RS, et al. (1991). Phase II trial of pentostatin in refractory lymphoma and cutaneous T-cell disease. J Clin Oncol 9:565–571.

    PubMed  CAS  Google Scholar 

  49. Foss F, Fischmann A, Schechter G, et al. (1989). Phase II trial of pentostatin and interferon-alpha-2A in advanced mycosis fungoides/Sezary syndrome. Proc Am Soc Clin Oncol 8:276 (abstract).

    Google Scholar 

  50. Hochester HS, Kim K, Green MD, et al. (1992). Activity of fludarabine in previously treated non-Hodgkin’s low-grade lymphoma: results of an Eastern Cooperative Oncology Group Study. J Clin Oncol 10:28–32.

    Google Scholar 

  51. Duggan DB, Anderson JR, Dillman R, Case P, Gottlieb AJ (1990). 2′deoxycoformycin (pentostatin) for refractory non-Hodgkin’s lymphoma: a CALGB phase II study. Med Pediatr Oncol 18:203–206.

    Article  PubMed  CAS  Google Scholar 

  52. Kantarjian HM, Alexanian R, Koller C, et al. (1990). Fludarabine therapy in macro-globulinemic lymphomas. Blood 75:1928–1931.

    PubMed  CAS  Google Scholar 

  53. Bruera E, Villamayor R, Roca E, Barugel M, Tronge J, Chacon R (1985). Response of Waldenstrom’s macroglobulinemia to pentostatin (2′-deoxycoformycin). Cancer Treat Rep 70:546–549.

    Google Scholar 

  54. Dearden C, Matutes E, Catovsky D (1991). Deoxycoformycin in the treatment of mature T-cell leukemias. Br J Cancer 64:903–906.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Alan Saven
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lawrence D. Piro
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Hematology, M.D. Anderson Cancer Center, Houston, Texas, USA

    Fernando Cabanillas M.D.  & M. Alma Rodriguez M.D.  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

Saven, A., Piro, L.D. (1997). 2-Chlorodeoxyadenosine treatment of lymphoma. In: Cabanillas, F., Rodriguez, M.A. (eds) Advances in Lymphoma Research. Cancer Treatment and Research, vol 85. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4129-5_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-4129-5_2

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6851-9

  • Online ISBN: 978-1-4615-4129-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation